Asia-Pacific NSCLC market to more than double to $6.2bn by 2023

pharmafile | March 21, 2017 | News story | Manufacturing and Production, Research and Development, Sales and Marketing BMS, Eli Lilly, MSD, NSCLC, Yervoy, keytruda, opdivo 

New research from intelligence provider GBI Research has indicated that the non-small cell lung cancer (NSCLC) market in the Asia-Pacific (APAC) region is set to grow by more than 100% to be worth $6.2 billion by 2023, up from $3 billion in 2016. The advent of key therapies including BMS’ Yervoy (ipilimumab) and necitumumab, also known as Eli Lilly’s Portrazza is given as primary drivers of this growth.

Another key development in the region is the approval of immune-checkpoint inhibitors including BMS’ Opdivo, which has received marketing authorisation in Australia, South Korea and Japan, and MSD’s Keytruda, which so far has only been approved in Japan, but will soon move to widen that approval through data generated in current Phase 3 trials.  

“Owing to strong clinical performances, immune-checkpoint inhibitors will have a greater uptake than other second-line market entrants and will compete among themselves for market share in the APAC region,” GBI Analyst Gayathri Kanika explained. “Chemotherapy will remain an integral aspect of NSCLC treatment, with platinum-based regimens being crucial in the first-line setting for all patients and docetaxel being a key therapy for second-line patients.”

Kanika also expects the market share of generic medications to shrink as a result of these targeted therapies entering the market. Interestingly, she also notes that this influx of new medicines will increase market segmentation and affect the determination of treatment options: “Broadly speaking, histological and molecular characterisation of tumours will play an even more important role in determining the best treatment options in the NSCLC market.”

Finally, these premium therapies will also have an effect on the impact of patent expiries within the sector, as Kanika notes: “The entry of targeted therapies into the market will offset the effect of patent expiries for drugs such as Avastin, Alimta, and Tarceva, which will have a limited impact on the market between 2016 and 2023. Indeed, the limited effect of patent expiry on the NSCLC market is one of the main reasons for the substantial growth in value expected in the forecast period, as the introduction of numerous premium therapies will not be offset by generic erosion.”

Matt Fellows

Related Content

BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910

Swedish clinical stage biotech company BioInvent has announced that it has received Investigational New Drug …

Bristol Myers Squibb’s NDA accepted by FDA

Global pharmaceutical company Bristol Myers Squibb (BMS) has announced that its New Drug Application (NDA) …


Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s …

Latest content